{"id":"W3013209996","doi":"10.1016/j.jchf.2020.03.002","title":"Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction","year":2020,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Center for Advancing Translational Sciences; National Heart, Lung, and Blood Institute; National Medical Research Council; Baxter Healthcare Corporation; National Institutes of Health; Vifor Pharma; Daiichi-Sankyo; Kidney Research UK; Bayer Fund; Actavis; Boston Scientific Corporation; KU Leuven; Takeda Pharmaceuticals U.S.A.; Sanofi Pasteur; United Therapeutics Corporation; Cytokinetics; AbbVie; Novo Nordisk; MyoKardia; Servier; Bayer; Gilead Sciences; Medtronic; Sanofi; Roche; Novartis; Merck; GlaxoSmithKline; Akebia Therapeutics; Bristol-Myers Squibb; AstraZeneca; Actelion Pharmaceuticals; Pfizer; Boehringer Ingelheim; Amgen; American Heart Association; Abbott Laboratories","keywords":"Medicine; Heart failure; Sacubitril; Sacubitril, Valsartan; Natriuretic peptide; Ejection fraction; Valsartan; Internal medicine; Cardiology; Heart failure with preserved ejection fraction; Blood pressure","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001095106,0.000582957,0.001130459,0.0001706134,0.0001751557,0.0003818268,0.0002615838,0.0003949009,0.001110808],"category_scores_gemma":[0.001066848,0.0001899877,0.0007456825,0.0001374035,0.0003606198,0.0003100729,0.0001529409,0.001090562,0.0001468646],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002611856,"about_ca_system_score_gemma":0.0004444888,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004981551,"about_ca_topic_score_gemma":0.00165481,"domain_scores_codex":[0.9996383,0.0001958662,0.00003131341,0.00004316687,0.00002824588,0.00006305709],"domain_scores_gemma":[0.9993624,0.0001951003,0.000112797,0.00004835513,0.00003756837,0.0002437733],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8397619,0.01400054,0.01240828,0.0004942405,0.001956141,0.0001836825,0.00009398034,0.001452773,0.02294511,0.0001611765,0.0007581389,0.1057841],"study_design_scores_gemma":[0.2862962,0.577022,0.1177675,0.000073706,0.002660013,0.0003821034,0.0001295234,0.00283214,0.0109606,0.0003748958,0.001456829,0.00004440293],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975349,0.001646943,0.00005163714,0.0001142726,0.00005978468,0.0000487111,0.00007693794,0.00001350159,0.0004533221],"genre_scores_gemma":[0.9987956,0.0004875666,0.0001333163,0.0001323761,0.00007917415,0.00003595385,0.0001101228,0.000002715186,0.0002231567],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001130459,"threshold_uncertainty_score":0.005791545,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01475409723559611,"score_gpt":0.2656894741211548,"score_spread":0.2509353768855587,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}